表紙:コレステリルエステル転送タンパク質 (脂質転送タンパク質、CETP) - パイプライン製品の分析
市場調査レポート
商品コード
358691

コレステリルエステル転送タンパク質 (脂質転送タンパク質、CETP) - パイプライン製品の分析

Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 50 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.07円
コレステリルエステル転送タンパク質 (脂質転送タンパク質、CETP) - パイプライン製品の分析
出版日: 2020年10月30日
発行: Global Markets Direct
ページ情報: 英文 50 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コレステリルエステル転送タンパク質 (CETP) は、血漿脂質転送タンパク質としても知られ、コレステリルエステルの転送を促進する血漿タンパク質です。

当レポートでは、コレステリルエステル転送タンパク質 (脂質転送タンパク質、CETP) の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなど、体系的な情報を提供しています。

目次

イントロダクション

概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療分野別
  • 開発中の製品:適応別

パイプライン製品の概要

  • 後期段階の製品
  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の評価

  • 単剤/併用療法別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Chong Kun Dang Pharmaceutical Corp.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
  • Pipeline by DalCor Pharmaceuticals Inc, H2 2020
  • Pipeline by NewAmsterdam Pharma BV, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020
  • Discontinued Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020 (Contd..2), H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
目次
Product Code: GMDHC2629TDB

Summary:

According to the recently published report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020'; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020' outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Cardiovascular which include indications Dyslipidemia, Acute Coronary Syndrome and Cardiovascular Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Co
  • Chong Kun Dang Pharmaceutical Corp
  • DalCor Pharmaceuticals Inc
  • NewAmsterdam Pharma BV
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
  • CKD-508 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CKD-519 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dalcetrapib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HL-16 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • obicetrapib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CETP for Cardiovascular Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 27, 2020: DalCor announces dal-GenE trial continues with final data expected in the first half of 2021
  • Jan 27, 2020: Dalcor announces Dal-gene trial to continue as planned following interim futility analysis
  • Dec 17, 2018: Dalcor announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease
  • Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
  • Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
  • Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
  • Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule
  • Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
  • Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
  • Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
  • Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
  • Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
  • Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
  • Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease
  • Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer